HLA-A*33 antigen

Also Known As:

A-3301; A-3302; HLA A33; HLA A33, subtype A-3302; HLA Aw33; HLA Aw33 antigen; HLA-A*3303; HLA-A*33:02 antigen; HLA-A*33:03 antigen; HLA-A33; HLA-A33, subtype A-3302; HLA-A33, subtype A-3303; HLA-Aw33

Networked: 26 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class I: 1944
        HLA-A Antigens: 2452
        HLA-A*33 antigen: 26
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class I: 1944
        HLA-A Antigens: 2452
        HLA-A*33 antigen: 26
  - Membrane Proteins: 10078
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class I: 1944
        HLA-A Antigens: 2452
        HLA-A*33 antigen: 26
Biological Factors: 2472
- Antigens: 143924
  - Surface Antigens: 5813
    - Histocompatibility Antigens: 1132
      - HLA Antigens: 8934
        HLA-A Antigens: 2452
        HLA-A*33 antigen: 26
      - Histocompatibility Antigens Class I: 1944
        HLA-A Antigens: 2452
        HLA-A*33 antigen: 26
  - Isoantigens: 1221
    - Histocompatibility Antigens: 1132
      - HLA Antigens: 8934
        HLA-A Antigens: 2452
        HLA-A*33 antigen: 26
      - Histocompatibility Antigens Class I: 1944
        HLA-A Antigens: 2452
        HLA-A*33 antigen: 26

Experts

1.	Itoh, Kyogo: 5 articles (02/2009 - 02/2004)
2.	Shichijo, Shigeki: 4 articles (02/2009 - 02/2004)
3.	Takedatsu, Hiroko: 4 articles (04/2007 - 02/2004)
4.	Noguchi, Masanori: 3 articles (02/2009 - 10/2005)
5.	Azuma, Koichi: 2 articles (04/2007 - 04/2004)
6.	Harada, Mamoru: 2 articles (04/2007 - 10/2005)
7.	Matsueda, Satoko: 2 articles (04/2007 - 10/2005)
8.	Sasada, Tetsuro: 2 articles (04/2007 - 04/2004)
9.	Cui, Huixia: 1 article (01/2013)
10.	Hu, Wei: 1 article (01/2013)

Related Diseases

1.	Neoplasms (Cancer) 04/15/2004 - "Three IEX-1-derived peptides at positions 47-56, 61-69, and 65-73, which were recognized by the 850B-CTLs, could induce CD8(+) peptide-specific CTL reaction to tumor cells from HLA-A33(+) gastric cancer patients and other epithelial cancer patients, but not from healthy donors, in an HLA class I-restricted manner. " 02/01/2004 - "One RLI- or KIAA0036-derived peptide induced tumor-reactive CTLs in PBMCs of HLA-A3(+) and -A11(+) or HLA-A11(+) and -A33(+) cancer patients also with various frequencies (22-67%), respectively, whereas the other peptide induced CTL activity in only HLA-A33(+) patients. " 04/15/2004 - "Because increased expression of IEX-1 is suggested to be involved in the resistance to apoptosis and in the proliferation of cancer cells, these antigenic peptides could be potent candidates for peptide-based specific immunotherapy against HLA-A33(+) gastric cancer and other epithelial cancers." 10/01/2005 - "These peptides efficiently induced peptide-specific and prostate cancer-reactive CTLs from PBMCs of cancer patients with the HLA-A11, HLA-A31, and HLA-A33 alleles. " 11/01/1998 - "This protein has been identified as a melanoma antigen recognized by tumor reactive CTLs derived from tumor infiltrating lymphocytes in the context of HLA-A31 and HLA-A33. "
2.	Postherpetic Neuralgia 12/01/2002 - "Association of HLA-A3303-B4403-DRB1*1302 haplotype, but not of TNFA promoter and NKp30 polymorphism, with postherpetic neuralgia (PHN) in the Japanese population." 03/01/1999 - "HLA-A33 and -B44 and susceptibility to postherpetic neuralgia (PHN)."
3.	Prostatic Neoplasms (Prostate Cancer) 10/01/2005 - "These peptides efficiently induced peptide-specific and prostate cancer-reactive CTLs from PBMCs of cancer patients with the HLA-A11, HLA-A31, and HLA-A33 alleles. " 02/01/2009 - "This peptide induced cancer cell-reactive cytotoxic T lymphocytes from peripheral blood mononuclear cells of both healthy donors and prostate cancer patients with HLA-A11, HLA-A31 and HLA-A33 alleles, but not with HLA-A2. " 10/01/2005 - "These peptides were first screened for their ability to be recognized by immunoglobulin G (IgG) of prostate cancer patients and subsequently for the potential to induce peptide-specific and prostate cancer-reactive CTLs from peripheral blood mononuclear cells (PBMC) of cancer patients with the HLA-A11, HLA-A31, and HLA-A33 alleles. "
4.	Infections 12/01/2008 - "HLA-A33 is associated with susceptibility to enterovirus 71 infection." 03/01/2009 - "HLA-A 3303 and *3301 predispose patients to persistent hepatitis B infection." 12/01/2008 - "HLA-A33, which is a common phenotype in Asian populations but is rare in white populations, was most significantly associated with enterovirus 71 infection, compared with the other candidate genes we studied, whereas HLA-A2 was significantly related to cardiopulmonary failure."
5.	Erythema Multiforme 09/01/1988 - "Erythema multiforme is associated to HLA-Aw33 and DRw53." 10/01/1994 - "We have been unable to confirm an association of HLA-A33 or HLA-DQ3 with erythema multiforme. " 10/01/1994 - "Previous reports have shown an increased frequency of certain HLA antigens in association with erythema multiforme, including HLA-B15(B62), HLA-B35, HLA-A33, HLA-DR53 and, more recently, HLA-DQB1*0301. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	HLA-A11 Antigen
3.	HLA-A31 antigen
4.	HLA-A3 Antigen (HLA A3 Antigen)
5.	Antigens
6.	HLA-B35 Antigen (HLA B35 Antigen)
7.	HLA-A2 Antigen (HLA A2 Antigen)
8.	HLA-A Antigens (HLA-A)
9.	Vaccines
10.	HLA Antigens (Human Leukocyte Antigens)

Related Therapies and Procedures

1.	Immunotherapy